OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Acquired by Empowered Funds LLC

Empowered Funds LLC lifted its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 22.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 359,419 shares of the medical instruments supplier’s stock after buying an additional 66,210 shares during the quarter. Empowered Funds LLC owned approximately 0.48% of OraSure Technologies worth $1,535,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of OraSure Technologies by 1.9% during the first quarter. Vanguard Group Inc. now owns 5,409,028 shares of the medical instruments supplier’s stock worth $33,266,000 after purchasing an additional 99,572 shares in the last quarter. Renaissance Technologies LLC increased its holdings in OraSure Technologies by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock valued at $9,749,000 after purchasing an additional 391,100 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of OraSure Technologies by 38.1% in the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after buying an additional 605,324 shares during the period. Millennium Management LLC lifted its position in shares of OraSure Technologies by 727.5% during the second quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier’s stock worth $8,610,000 after purchasing an additional 1,776,867 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in OraSure Technologies by 30.1% in the 2nd quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock valued at $7,710,000 after buying an additional 418,603 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Price Performance

Shares of OSUR opened at $3.85 on Friday. OraSure Technologies, Inc. has a 12-month low of $3.72 and a 12-month high of $8.45. The business’s fifty day moving average price is $4.16 and its 200 day moving average price is $4.37. The stock has a market capitalization of $287.17 million, a PE ratio of 25.40 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm had revenue of $39.92 million for the quarter, compared to analysts’ expectations of $38.97 million. During the same period in the previous year, the business earned $0.27 earnings per share. OraSure Technologies’s revenue for the quarter was down 55.2% compared to the same quarter last year. As a group, research analysts anticipate that OraSure Technologies, Inc. will post -0.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on OSUR shares. Evercore ISI boosted their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research note on Wednesday, August 7th. StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 4th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.